Abstract
In contrast to typical atrial flutter, atypical atrial flutter is a heterogeneous group of right and left atrial macro- or localized reentry tachycardias whose critical component for maintaining tachycardia is not the cavotricuspid isthmus. Atypical atrial flutter occurs more frequently after previous catheter ablation and after cardiac surgery. The intraprocedural success rate during ablation is high, although the recurrence rate depends on structural changes in the atria as well as the underlying mechanism. This article provides an overview of the mechanisms as well as mapping and ablation strategies of the most common forms of right and left atrial atypical atrial flutter. This article is part of the “EP Basics” series for targeted continuing education in invasive electrophysiology. Basics, clinic and therapy of atypical atrial flutter are presented with focus on clinically relevant aspects. Procedures and findings of invasive electrophysiological diagnostics and ablation treatment are the focus of this article.
| Translated title of the contribution | Atypical atrial fibrillation: Diagnostics and therapy |
|---|---|
| Original language | German |
| Journal | Herzschrittmachertherapie und Elektrophysiologie |
| Volume | 33 |
| Issue number | 3 |
| Pages (from-to) | 341-350 |
| Number of pages | 10 |
| ISSN | 0938-7412 |
| DOIs | |
| Publication status | Published - 09.2022 |
Funding
A. Rillig: consultant fees and travel grants or study support form Biosense Webster, Medtronik, EPD/Philips, Cardiofocus, Ablamap and Abbott. D. Steven: speakers honoraria from Abbott, Boston Scientific and Biosense Webster and research grants from Medtronic, Abbott and Biosense Webster. T. Althoff: research grants for investigator-initiated trials from Biosense Webster. T. Maurer: Speaker honoraria/travel grants from Abbott, Biosense Webster, Medtronic, and Philips. V. Johnson: speaker and travel fee, fellowship Grant von Abbott Medical, Biotronik SE, Boston Scientific, Medtronic, Pfizer, BMS, Zoll, Astra Zeneca, Boehringer Ingelheim and Bayer Vital GmbH. L. Iden: consultant honoraria/lecture fees from Biosense Webster, Biotronik, Medtronic. D. Duncker: speaker honoraria from Abbott, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CVRx, Medtronic, Pfizer, Zoll. P. Sommer: Advisory Board Abbott, Biosense Webster, Boston Scientific, and Medtronic. M. Kottmaier: consultant, speaker and travel fee Abbott, Biosense Webster, Boston Scientific. T. Reents: consultant, speaker and travel fee Abbott, Biosense Webster, Boston Scientific. F. Bourier: consultant, speaker and travel fee Abbott, Biosense Webster, Boston Scientific. R. Tilz: received travel grants from St. Jude Medical, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Boston scientific, Abbott, Bristol-Myers Squibb, Bayer, Sanofi Aventis, and research grants by Cardiofocus, Boston Scientific and Lifetech. A. Metzner: Advisory board: Medtronic, Biosense Webster; lecture honoraria: Medtronic, Biosense Webster, Boston Scientific, Cardiofocus, Bayer. S. Busch, D.-I. Shin, H. Estner, K. R. J. Chun, H. Jansen, A. Jadidi und C. Ewertsen geben an, dass kein Interessenkonflikt besteht.
Research Areas and Centers
- Centers: Cardiological Center Luebeck (UHZL)
DFG Research Classification Scheme
- 2.22-12 Cardiology, Angiology
